Aspira Women’s Health 

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aspira Women's Health (AWH) sees robust growth and innovation in Q1 2024

Aspira Women's Health (AWH) reported strong performance in Q1 2024, driven by significant growth in test volumes and improvements in financial metrics. The company's focus on innovation and collaboration underscores its commitment to advancing women's health diagnostics. While challenges in funding persist, AWH's strategic initiatives and market opportunities position it for continued growth and success in the future.

Aspira Women's Health achieves record test volumes amidst cost challenges

AWH reported strong performance in test volumes and revenue growth in Q2 2024.
While facing challenges with margins and costs, the company is actively addressing them.
Opportunities lie in product development, market expansion, and cost control measures.
Overall, AWH is strategically positioned for growth and innovation in the women's health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aspira (AWH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aspira (AWH) Upgraded to Buy: What Does It Mean for the Stock?

AUSTIN, Texas, June 02, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, announced today that it has received notification from the Listing Qualifications Department (“the Staff”) of the Nasdaq Stock Market (“Nasdaq”) that Aspira has regained compliance with the Nasdaq minimum bid price requirement, as is required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”), based on achieving the minimum closing bid price per share for 10 consecutive business days. The Notice also indicated that because the Company is now in compliance with the Bid Price Requirement, Nasdaq considers the matter closed.

Aspira Women's Health Regained Compliance with Nasdaq's Minimum Bid Price Requirement

AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, announced the online publication of three abstracts supporting the clinical utility of OvaWatchSM at the 2023 American Society of Clinical Oncology (ASCO) Meeting taking place in Chicago, Il on June 2-6, 2023. These abstracts were co-authored by the Aspira Women's Health Innovation Team and Dr. Gerard Reilly, Director of Clinical Research and Innovation at Axia Women's Health.

Aspira Women's Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests

AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will participate in William Blair's 43rd Annual Growth Stock Conference taking place in Chicago, Illinois on June 6-8, 2023. Management will attend 1:1 meetings with investors who are registered for the conference.

Aspira Women's Health to Participate at William Blair's 43rd Annual Growth Stock Conference

AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it would present at the upcoming 2023 American College of Obstetricians and Gynecologists (“ACOG”) Annual Clinical & Scientific Conference being held in Baltimore, MD on May 19-21, 2023.

Aspira Women's Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference

AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has appointed Torsten Hombeck, Ph.D., as Chief Financial Officer, replacing interim CFO Marlene McLennan. Dr. Hombeck brings to Aspira extensive experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings. The change will be effective on June 15, 2023.

Aspira Women's Health Names Torsten Hombeck as Chief Financial Officer

AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it will host a virtual Investor Day on Tuesday, May 23, 2023 at 1:00pm ET. Click here to register.

Aspira Women's Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023

Aspira Women's Health Inc. (NASDAQ:AWH ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Marlene McLennan - Interim Chief Financial Officer Conference Call Participants Sally Yanchus - Water Tower Research Operator Good afternoon ladies and gentlemen and welcome to Aspira Women's Health, Incorporated First Quarter 2023 Earnings Conference Call. During the presentation all participants will be in a listen-only mode.

Aspira Women's Health Inc. (AWH) Q1 2023 Earnings Call Transcript

First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a decrease of 44% year-over-year Conference Call and Webcast scheduled for today 4:30 pm Eastern Time AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the first quarter ended March 31, 2023. “We saw record growth in both revenues and volume in the first quarter of 2023.

Aspira Women's Health® Reports First Quarter 2023 Financial Results

AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic, tools, today announced a 1-for-15 reverse stock split of its outstanding common stock, effective at 12:01 am Eastern time on May 11, 2023. Beginning tomorrow, May 12, 2023, the Company's common stock will trade on a split-adjusted basis.

Aspira Women's Health Announces 1-for-15 Reverse Stock Split

Apollo Medical Hlds

McDonald's

Paycor HCM

Sandstorm Gold

AMEH, PYCR, AWH, SAND and MCD have been added to the Zacks Rank #1 (Strong Buy) List on May 11, 2023.

New Strong Buy Stocks for May 11th

AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it the appointment of three new independent directors: Stefanie Cavanaugh, Jannie Herchuck, and Lynn O'Connor Vos.

Aspira Women's Health Appoints Three New Members to its Board of Directors

Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company's history

Aspira Women's Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023

What Makes Aspira (AWH) a New Buy Stock

Aspira Women's Health Inc. (NASDAQ:AWH ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Nicole Sandford - President & Chief Executive Officer Ryan Phan - Chief Scientific Officer & Chief Operating Officer Marlene McLennan - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair Operator Good morning ladies and gentlemen and welcome to Aspira Women's Health, Inc. Fourth Quarter and Year-End 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Aspira Women's Health Inc. (AWH) Q4 2022 Earnings Call Transcript

Aspira (AWH) delivered earnings and revenue surprises of 33.33% and 10.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aspira (AWH) Reports Q4 Loss, Misses Revenue Estimates

2022 total revenue of $8.2 million, an increase of 20% year-over-year

Aspira Women's Health Reports Fourth Quarter and Full Year 2022 Financial Results

Here is how Aspira (AWH) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.

Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year?

AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bio-analytical based women's health company focused on gynecologic disease, today announced that the company will report its financial results for the year ended December 31, 2022 after the market closes on Wednesday, March 22, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the call are below:

Aspira Women's Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023

First National Payer to Cover OvaWatch First National Payer to Cover OvaWatch

Aspira Women's Health Announces National Payer Coverage for OvaWatch

Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021

Aspira Women's Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights

Provides clinical validation for the use of OvaWatch SM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses

Aspira Women's Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses

Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatch SM , through the 2023 Omnibus Spending Bill

Aspira Women's Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, announced the commercial launch of OvaWatchSM, a new non-invasive blood-based test for the assessment of ovarian cancer risk in women with adnexal masses. OvaWatch is part of the Company's OvaSuiteSM portfolio of commercialized ovarian cancer risk assessment tests, including FDA-cleared assays Ova1® and Overa® (Ova1Plus®). With limited exceptions, U.S. physicians will be able to order the test for their patients starting December 1, 2022.

Aspira Women's Health Announces the Commercial Launch of OvaWatch(SM)

Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Nicole Sandford - President and Chief Executive Officer Ryan Phan - Chief Scientific Officer and Chief Operating Officer Robert Beechey - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Griffin Soriano - William Blair & Company Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health Incorporated Third Quarter 2022 Conference Call. My name is David, and I will be your coordinator for the call today.

News for Aspira Women’s Health Stock (AWH)